Background and Drug Information on Generic Approval

The U.S. Food and Drug Administration (FDA) has granted final approval for ANDA 207419, a generic oxycodone/acetaminophen combination drug developed by Ascent Pharmaceuticals, Inc. This combination drug uses Endo Pharmaceuticals' Percocet as the reference listed drug (RLD). It combines oxycodone hydrochloride, an opioid analgesic, with acetaminophen, a non-opioid analgesic. Oxycodone is an agonist that acts on the mu-opioid receptor (MOR), and acetaminophen provides synergistic pain relief through COX inhibition and TRPV1 regulation. This approval contributes to providing affordable alternative medications after patent expiration, reducing the financial burden of medications for patients, and improving access to treatment.

Distribution Cooperation between Camber and XL Care and Diversification of Supply Chain

This regulatory information update confirms that Camber Pharmaceuticals, Inc., and XL Care Pharmaceuticals, Inc., are leading the market supply through primary distribution and repackaging. The combination drug, which combines the two ingredients into one, improves patient compliance and ease of administration by reducing the number of pills taken. Furthermore, it is clinically important to safely manage severe pain by limiting the dose of the opioid component, oxycodone, while leveraging the complementary effect with acetaminophen. Ascent's manufacturing capabilities and the distribution cooperation between Camber and XL Care positively contribute to maintaining the stability of the pharmaceutical supply chain in the United States.

Scale and Dynamics of the U.S. Opioid Analgesic Market

The U.S. market for oxycodone/acetaminophen combination drugs is a major pharmaceutical category with an annual value of approximately $1.8 billion (USD) in 2023 and approximately 12.5 million prescriptions per quarter. However, due to the opioid crisis in the United States and the strict guidelines from the CDC, the number of prescriptions is declining by approximately 5% annually. Furthermore, global generic giants such as Mallinckrodt, AMRX, and TEVA are competing for market share, resulting in intense price competition among distributors. Therefore, distributors are focusing on securing long-term supply contracts with prescription drug chain pharmacies and ensuring the reliability of quality control as key competitive advantages.

VC and Investment Perspective in Light of Intensified Generic Competition

From the perspective of institutional investors and venture capitalists (VCs), it is important to focus on maintaining stable operating cash flow rather than short-term revenue growth due to regulatory barriers and tight margins. In particular, the ability to minimize regulatory compliance risks and control supply chain costs under the control of the U.S. Drug Enforcement Administration (DEA) for raw material quotas is a criterion for long-term survival. In the future, the ability to develop non-opioid analgesics or abuse-deterrent formulations (ADF) will likely determine the long-term valuation premium. Investors should closely monitor how individual companies circumvent regulatory risks and maintain market share in a solidified market structure.